On the contrary, melanomas with BRAF class-2 mutations (non-V600 mutations) do not respond to first-generation BRAF inhibitors, which are monomer selective, but they could be of benefit to MEK/ERK inhibitors as well as the BRAF inhibitor PLX8394 (Dahlman et al., 2012; Bowyer et al., 2014; Marconcini et al., 2017; Janku et al., 2018). The gene discussed is MAP2K7; the disease is melanoma.